A Study to Test MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: MK0941 (Drug); glimepiride (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Merck

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck

Overall contact:
Toll Free Number, Phone: 1-888-577-8839

The purpose of this study is to test the effect of MK0941 as add-on therapy for patients taking metformin for Type II Diabetes.

Official title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study

Primary outcome: Assess the effect of the addition of MK0941 compared to glimepiride on 24-hour weighted mean glucose when added to metformin

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient has type 2 diabetes mellitus

- Between the ages of 18 and 70

Exclusion Criteria:

- Patient has a history of type 1 Diabetes Mellitus or ketoacidosis.

- Patient is on a weight loss program and is not in the maintenance phase or is taking

weight loss medication.

- Patient has had surgery within 30 days of starting the study or has planned major

surgery during the study

Toll Free Number, Phone: 1-888-577-8839

Merck Sharp & Dohme (Australia) Pty Ltd., South Granville NSW 2142, Australia; Recruiting
David Woolner, Phone: 64-9-523-6075

Merck Sharp & Dohme, Glostrup 2600, Denmark; Recruiting
Christina Wengel, Phone: 45-43-28-77-90

MSD Finland Oy, Espoo 2151, Finland; Recruiting
Eero Helve, Phone: 358-9-804-65280

MSD Pharmaceuticals Private Ltd., New Delhi 110011, India; Recruiting
Swashraya Shah, Phone: 91-124-464-7338

Merck Sharp & Dohme (Italia) S.P.A., Roma 191, Italy; Recruiting
Gianfranco Botta, Phone: 39 06 36 191187

Merck Sharp & Dohme (I.A.) Corp, Selangor 46300, Malaysia; Recruiting
Nazrin Azli, Phone: 603-77181748

MSD (Norge) AS, Drammen 3011, Norway; Recruiting
Gunnar Saeter, Phone: 47 32 20 7460

MSD Polska Sp. z o.o. Dzial Medyczny, Warszawa 00-867, Poland; Recruiting
Adam Czernik, Phone: 48 22 549-51-39

Merck Sharp & Dohme IDEA, Inc., Moscow 121059, Russian Federation; Recruiting
Tatiana Serebriakova, Phone: 7-495-941-8264

Merck Sharp & Dohme (Sweden) AB, Sollentuna 192 07, Sweden; Recruiting
Roger Juhlin, Phone: 46-8-626-1 458

Merck Sharp & Dohme (I.A.) Corp., Taipei [106, Taiwan; Recruiting
Avery Basil Ince, Phone: 886 2 23761610

Call for Information, Anniston, Alabama 36207, United States; Recruiting

Call for Information, Walnut Creek, California 94598, United States; Recruiting

Frosst Laboratories Inc., Bogota, Cundinamarca, Colombia; Recruiting
Felipe Arbelaez, Phone: 57-1-592-4400

Merck Sharp & Dohme (Ireland), Leopardtown, Dublin 18, Ireland; Recruiting
Colm Galligan, Phone: 353-1-2998770

Merck Sharp & Dohme IDEA, Inc., Tallinn, Eesti 11415, Estonia; Recruiting
Andrius Bacevicius, Phone: 370-5-2780-243

Call for Information, Springfield, Illinois 62704, United States; Recruiting

Call for Information, Chicago, Illinois 60612, United States; Recruiting

Call for Information, Berlin, New Jersey 08009, United States; Recruiting

Call for Information, Winston-Salem, North Carolina 27103-3914, United States; Recruiting

Merck Frosst Canada Ltd., Kirkland, Quebec H9H 3L1, Canada; Recruiting
Michel Cimon, Phone: 514-428-2605

Call for Information, Renton, Washington 98057, United States; Recruiting

Starting date: January 2009
Ending date: January 2010
Last updated: October 7, 2009